Aml Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
U
CC-486 and Venetoclax for Acute Myeloid Leukemia
Recruiting
  • AML
  • Aurora, Colorado
  • +1 more
2022-04-04
Apr 4, 2022
M
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Recruiting
  • MDS
  • AML
  • Bronx, New York
    Montefiore Medical Center
2022-03-24
Mar 24, 2022
H
Study Augmenting TAK-659 Action in Relapsed/Refractory AML by Addition Ofthe Proteasome Inhibitor Ixazomib - 2022
Terminated
  • AML
  • AML, Adult
  • Indianapolis, Indiana
    Indiana University Melvin and Bren Simon Cancer Center
2022-03-15
Mar 15, 2022
D
GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG
Recruiting
  • Graft Vs Host Disease
  • +5 more
  • Augsburg, Germany
  • +15 more
2022-03-21
Mar 21, 2022
G
Registry of Patients Having Received oNKord®
Not yet recruiting
  • AML
  • oNKord®
  • Cyclophosphamide/Fludarabine (Cy/Flu)
  • (no location specified)
2022-03-21
Mar 21, 2022
M
Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)
Active, not recruiting
  • AML
  • Flotetuzumab dose escalation
  • +2 more
  • Duarte, California
  • +42 more
2022-03-07
Mar 7, 2022
M
A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure
Not yet recruiting
  • AML
  • MDS
  • Houston, Texas
    M D Anderson Cancer Center
2022-03-08
Mar 8, 2022
S
Phase I/II Trial of CPX-351 + Palbociclib in Patients With Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • AML
  • Cleveland, Ohio
    Cleveland Clinic Taussig Cancer institute, Case Comprehensive Ca
2022-03-16
Mar 16, 2022
J
A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Recruiting
  • NSCLC
  • +7 more
  • Tianjin, Tianjin, China
    Tianjin
2022-03-11
Mar 11, 2022
U
Cardioprotection in AML
Recruiting
  • AML
  • Acute Myeloid Leukemia
  • Charlottesville, Virginia
    University of Virginia
2022-03-09
Mar 9, 2022
G
Venetoclax in Patients With MDS or AML in Relapse After AHSCT
Not yet recruiting
  • MDS
  • AML
  • venetoclax + azacitidine +/- donor lymphocyte infusion
  • Amiens, France
  • +13 more
2022-03-09
Mar 9, 2022
J
A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Active, not recruiting
  • AML
  • MDS
  • Tianjin, Tianjin, China
    Blood disease hospital of Chinese Academy of Medical Sciences
2022-03-07
Mar 7, 2022
A
Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients - 2020
Completed
  • AML
  • Cytarabine (Phase 1 only)
  • +3 more
  • Los Angeles, California
  • +16 more
2022-02-22
Feb 22, 2022
Z
NK Cell Therapy for AML
Active, not recruiting
  • AML
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital，College of Medicine, Zhejiang Univ
2022-02-21
Feb 21, 2022
A
Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia
Active, not recruiting
  • Acute Myeloid Leukemia
  • +8 more
  • Gilbert, Arizona
  • +23 more
2022-02-22
Feb 22, 2022
Z
Clinical Study of CLL1 CAR-T Cells in the Treatment of Hematological Malignancies
Recruiting
  • AML
  • CLL1 CAR T-cells
  • Hangzhou, Zhejiang, China
  • +1 more
2022-02-13
Feb 13, 2022
Z
Clinical Study of CD38 CAR-T Cells in the Treatment of Hematological Malignancies
Recruiting
  • AML
  • CD38 CAR T-cells
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
2022-02-13
Feb 13, 2022
A
A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS
Recruiting
  • AML
  • +6 more
  • Gilbert, Arizona
  • +6 more
2022-02-08
Feb 8, 2022
A
Study of APVO436 in Patients With AML or MDS
Recruiting
  • AML
  • MDS
  • APVO436
  • San Francisco, California
  • +11 more
2022-02-08
Feb 8, 2022
P
Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias - 2021
Terminated
  • Leukemia, Myeloid, Acute
  • AML
  • Aurora, Colorado
  • +16 more
2022-01-18
Jan 18, 2022
B
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission
Active, not recruiting
  • Acute Myelogenous Leukemia
  • AML
  • DC AML Vaccine
  • Boston, Massachusetts
    Beth Israel Deaconess Medical Center
2022-01-25
Jan 25, 2022
C
A Phase 2 Study of Gemtuzumab Ozogamicin (GO)-Gilteritinib Combination in Adults With FLT3-ITD Relapse/Refractory (R/R) AML
Not yet recruiting
  • AML
  • Gemtuzumab ozogamicine - Cytarabine - Gilteritinib
  • (no location specified)
2022-01-05
Jan 5, 2022
M
Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Recruiting
  • AML
  • Hangzhou, Zhejiang, China
    The First Affiliated Hospital, Zhejiang University
2022-01-18
Jan 18, 2022
G
Prospective Study on Severe Infections on Acute Myeloid Leukemia (AML) Patients
Recruiting
  • AML
  • Adult
  • Observation
  • Civitanova Marche, Ancona, Italy
  • +45 more
2021-12-31
Dec 31, 2021
T
Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS
Recruiting
  • AML
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
2021-12-27
Dec 27, 2021